Medpace (NASDAQ:MEDP) Hits New 1-Year High After Strong Earnings

Medpace Holdings, Inc. (NASDAQ:MEDP)’s stock price hit a new 52-week high during trading on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $677.90 and last traded at $620.5350, with a volume of 153020 shares. The stock had previously closed at $528.12.

The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a return on equity of 109.14% and a net margin of 17.67%.The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter in the prior year, the business earned $3.10 earnings per share. The company’s quarterly revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS.

Trending Headlines about Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace reported second-quarter EPS of $4.25 and revenue of $707.3 million, both above expectations, showing that demand and execution remain strong. Medpace earnings report and conference call
• Positive Sentiment: The company raised fiscal 2026 guidance, signaling management has more confidence in its business momentum and future profitability. Medpace Soars After Q2 Beat, Strong Backlog Fuels Higher 2026 Outlook
• Positive Sentiment: Investors are also focusing on improving operating metrics, including a rebound in book-to-bill and a stronger backlog conversion rate, which suggest healthier future revenue visibility. Medpace: ‘Buy’ On Financial Metric Improvements And Solid Q2 2026 Earnings

Wall Street Analyst Weigh In

Several analysts have recently commented on MEDP shares. Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a research note on Thursday, July 2nd. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Leerink Partners set a $620.00 price target on shares of Medpace in a report on Thursday. Royal Bank Of Canada reduced their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a $535.00 price objective on shares of Medpace in a report on Thursday. Two analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $502.00.

Insider Activity at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares in the company, valued at $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 20.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On Medpace

Several institutional investors have recently modified their holdings of the company. Allspring Global Investments Holdings LLC lifted its holdings in Medpace by 164.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 3,653 shares of the company’s stock valued at $2,086,000 after purchasing an additional 2,274 shares in the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Medpace during the fourth quarter worth about $4,084,000. Cerity Partners LLC grew its holdings in shares of Medpace by 41.0% during the fourth quarter. Cerity Partners LLC now owns 80,973 shares of the company’s stock worth $45,478,000 after buying an additional 23,530 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in shares of Medpace by 24,930.4% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 101,373 shares of the company’s stock worth $56,936,000 after buying an additional 100,968 shares in the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Medpace by 881.1% in the fourth quarter. SG Americas Securities LLC now owns 60,144 shares of the company’s stock valued at $33,780,000 after buying an additional 54,014 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

The firm has a market cap of $17.30 billion, a price-to-earnings ratio of 35.51, a price-to-earnings-growth ratio of 2.64 and a beta of 1.15. The business’s 50-day moving average price is $488.37 and its two-hundred day moving average price is $493.74.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.